vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Perimeter Solutions, Inc. (PRM). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $102.8M, roughly 1.6× Perimeter Solutions, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 19.2%). Over the past eight quarters, Perimeter Solutions, Inc.'s revenue compounded faster (31.9% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Perimeter 81 is an Israeli cloud and network security company that develops secure remote networks, based on the zero trust architecture, for organizations. Its technology replaces legacy security appliances like VPNs and firewalls.

ESPR vs PRM — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.6× larger
ESPR
$168.4M
$102.8M
PRM
Growing faster (revenue YoY)
ESPR
ESPR
+124.6% gap
ESPR
143.7%
19.2%
PRM
Faster 2-yr revenue CAGR
PRM
PRM
Annualised
PRM
31.9%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
PRM
PRM
Revenue
$168.4M
$102.8M
Net Profit
$-140.2M
Gross Margin
45.2%
Operating Margin
50.6%
-160.7%
Net Margin
-136.5%
Revenue YoY
143.7%
19.2%
Net Profit YoY
-197.3%
EPS (diluted)
$0.32
$-0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
PRM
PRM
Q4 25
$168.4M
$102.8M
Q3 25
$87.3M
$315.4M
Q2 25
$82.4M
$162.6M
Q1 25
$65.0M
$72.0M
Q4 24
$69.1M
$86.2M
Q3 24
$51.6M
$288.4M
Q2 24
$73.8M
$127.3M
Q1 24
$137.7M
$59.0M
Net Profit
ESPR
ESPR
PRM
PRM
Q4 25
$-140.2M
Q3 25
$-31.3M
$-90.7M
Q2 25
$-12.7M
$-32.2M
Q1 25
$-40.5M
$56.7M
Q4 24
$144.2M
Q3 24
$-29.5M
$-89.2M
Q2 24
$-61.9M
$21.6M
Q1 24
$61.0M
$-82.6M
Gross Margin
ESPR
ESPR
PRM
PRM
Q4 25
45.2%
Q3 25
63.1%
Q2 25
62.4%
Q1 25
39.1%
Q4 24
48.6%
Q3 24
62.8%
Q2 24
57.6%
Q1 24
35.1%
Operating Margin
ESPR
ESPR
PRM
PRM
Q4 25
50.6%
-160.7%
Q3 25
-11.4%
-27.7%
Q2 25
8.6%
-16.1%
Q1 25
-34.0%
Q4 24
-6.4%
71.1%
Q3 24
-31.0%
-12.2%
Q2 24
3.5%
35.4%
Q1 24
52.5%
-126.8%
Net Margin
ESPR
ESPR
PRM
PRM
Q4 25
-136.5%
Q3 25
-35.9%
-28.7%
Q2 25
-15.4%
-19.8%
Q1 25
-62.2%
78.7%
Q4 24
167.2%
Q3 24
-57.2%
-30.9%
Q2 24
-83.9%
17.0%
Q1 24
44.3%
-139.8%
EPS (diluted)
ESPR
ESPR
PRM
PRM
Q4 25
$0.32
$-0.89
Q3 25
$-0.16
$-0.62
Q2 25
$-0.06
$-0.22
Q1 25
$-0.21
$0.36
Q4 24
$-0.14
$1.00
Q3 24
$-0.15
$-0.61
Q2 24
$-0.33
$0.14
Q1 24
$0.34
$-0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
PRM
PRM
Cash + ST InvestmentsLiquidity on hand
$167.9M
$325.9M
Total DebtLower is stronger
$669.1M
Stockholders' EquityBook value
$-302.0M
$1.1B
Total Assets
$465.9M
$2.7B
Debt / EquityLower = less leverage
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
PRM
PRM
Q4 25
$167.9M
$325.9M
Q3 25
$92.4M
$340.6M
Q2 25
$86.1M
$140.7M
Q1 25
$114.6M
$200.1M
Q4 24
$144.8M
$198.5M
Q3 24
$144.7M
$223.1M
Q2 24
$189.3M
$43.2M
Q1 24
$226.6M
$38.7M
Total Debt
ESPR
ESPR
PRM
PRM
Q4 25
$669.1M
Q3 25
$668.8M
Q2 25
$668.4M
Q1 25
$668.1M
Q4 24
$667.8M
Q3 24
$667.4M
Q2 24
$667.1M
Q1 24
$666.8M
Stockholders' Equity
ESPR
ESPR
PRM
PRM
Q4 25
$-302.0M
$1.1B
Q3 25
$-451.4M
$1.1B
Q2 25
$-433.5M
$1.2B
Q1 25
$-426.2M
$1.2B
Q4 24
$-388.7M
$1.2B
Q3 24
$-370.2M
$1.0B
Q2 24
$-344.2M
$1.1B
Q1 24
$-294.3M
$1.1B
Total Assets
ESPR
ESPR
PRM
PRM
Q4 25
$465.9M
$2.7B
Q3 25
$364.0M
$2.6B
Q2 25
$347.1M
$2.5B
Q1 25
$324.0M
$2.4B
Q4 24
$343.8M
$2.4B
Q3 24
$314.1M
$2.5B
Q2 24
$352.3M
$2.3B
Q1 24
$373.1M
$2.3B
Debt / Equity
ESPR
ESPR
PRM
PRM
Q4 25
0.59×
Q3 25
0.60×
Q2 25
0.57×
Q1 25
0.55×
Q4 24
0.58×
Q3 24
0.67×
Q2 24
0.62×
Q1 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
PRM
PRM
Operating Cash FlowLast quarter
$45.2M
$18.6M
Free Cash FlowOCF − Capex
$11.6M
FCF MarginFCF / Revenue
11.3%
Capex IntensityCapex / Revenue
0.0%
6.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$208.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
PRM
PRM
Q4 25
$45.2M
$18.6M
Q3 25
$-4.3M
$198.7M
Q2 25
$-31.4M
$-2.9M
Q1 25
$-22.6M
$23.7M
Q4 24
$-35.0M
$-6.0M
Q3 24
$-35.3M
$183.0M
Q2 24
$-7.2M
$8.6M
Q1 24
$53.8M
$2.8M
Free Cash Flow
ESPR
ESPR
PRM
PRM
Q4 25
$11.6M
Q3 25
$193.6M
Q2 25
$-15.6M
Q1 25
$18.9M
Q4 24
$-12.4M
Q3 24
$-35.5M
$179.1M
Q2 24
$-7.3M
$5.0M
Q1 24
$53.8M
$1.2M
FCF Margin
ESPR
ESPR
PRM
PRM
Q4 25
11.3%
Q3 25
61.4%
Q2 25
-9.6%
Q1 25
26.3%
Q4 24
-14.4%
Q3 24
-68.7%
62.1%
Q2 24
-9.9%
3.9%
Q1 24
39.0%
2.1%
Capex Intensity
ESPR
ESPR
PRM
PRM
Q4 25
0.0%
6.8%
Q3 25
0.0%
1.6%
Q2 25
0.0%
7.8%
Q1 25
0.0%
6.7%
Q4 24
0.0%
7.5%
Q3 24
0.3%
1.3%
Q2 24
0.1%
2.9%
Q1 24
0.1%
2.6%
Cash Conversion
ESPR
ESPR
PRM
PRM
Q4 25
Q3 25
Q2 25
Q1 25
0.42×
Q4 24
-0.04×
Q3 24
Q2 24
0.40×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

PRM
PRM

Products$87.7M85%
Service And Other$14.8M14%

Related Comparisons